Early introduction of oral paricalcitol in renal transplant recipients.

ABSTRACT: In stable renal transplant recipients with hyperparathyroidism, the vitamin D agonist paricalcitol reduces the level of proteinuria. Animal studies have indicated possible anti-fibrotic and anti-inflammatory effects of paricalcitol. We hypothesised that early introduction of paricalcitol in de novo renal transplant recipients would reduce proteinuria and counteract development of fibrosis in the allograft.

ORGANISM(S): Homo sapiens

PROVIDER: GSE83486 | GEO | 2017/09/01

SECONDARY ACCESSION(S): PRJNA326120

REPOSITORIES: GEO